PEG-Intron [peginterferon alfa-2b]/REBETOL [ribavirin] vs PEGIntron/SCH 503034 [boceprevir] with and without ribavirin in chronic hepatitis C HCV [hepatitis C virus]-1 peginterferon alfa/ribavirin null responders: a SCH 503034 dose-finding phase 2 study.
Latest Information Update: 06 May 2022
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RESPOND 1
- Sponsors Merck Sharp & Dohme Corp.
- 22 May 2008 Results were reported at the Digestive Disease Week 2008.
- 15 May 2008 Results reported at DDW 2008, according to a Schering-Plough media release (oral presentation 162; abstract 442360).
- 17 Apr 2008 Final results will be presented at the European Association for the Study of the Liver 43rd annual meeting in April 2008.